| Execution period | 5 years |
|---|
NSE filing, NSE: VAISHALI. Summary written from the filing by ALFA Finder's alert engine.
Vaishali Pharma Ltd: key numbers
- Share price
- ₹6.82
- Market cap
- ₹92.07 Cr
- Revenue (annual)
- ₹108.8 Cr
- Net profit (annual)
- ₹4.16 Cr
- P/E (TTM)
- 20.8×Sector 46.1×
- Promoter holding
- 31.61%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vaishali Pharma Ltd
All →Vaishali Pharma Preferential Issue
NSE has approved the listing of 45,37,865 equity shares allotted on a preferential basis by Vaishali Pharma Ltd, effective from October 16, 2026.
Vaishali Pharma Annual General Meeting
Vaishali Pharma Limited concluded its 19th Annual General Meeting on September 24, 2026, via video conferencing, transacting routine ordinary business matters.
Vaishali Pharma Capital Structure Change
Vaishali Pharma Ltd received listing approval from NSE for 45,37,865 equity shares issued on a preferential basis, subject to depository confirmation.
Vaishali Pharma Annual General Meeting
Vaishali Pharma Limited will hold its 19th Annual General Meeting on September 24, 2026, through video conferencing to transact ordinary business.
Vaishali Pharma Management Change
Vaishali Pharma Limited announced the resignation of Mr. Bhaveshkumar Popatlal Upadhyay from the position of Non-Executive Independent Director, effective August 14, 2026.
Vaishali Pharma Q1 FY27 Results: Net Profit ₹1.5 Cr, Up 15.4% YoY
Vaishali Pharma Ltd reported revenue from operations of ₹22.9 Cr (-3.4% YoY) and net profit of ₹1.5 Cr (+15.4% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.5 Cr · +15.4% YoY
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.